Dako and Quintiles form alliance to speed development of personalized medicine

Dako, a Danish-based world leader in tissue-based cancer diagnostics, and Quintiles, the world’s leading bio pharmaceutical services companies, announced a strategic alliance to advance personalized medicine by collaborating on the co-development of targeted therapies and companion diagnostics. Under the non-exclusive alliance, Dako and Quintiles will offer integrated drug-diagnostic development services and companion diagnostic products. The first such collaboration will support AstraZeneca in the development of one of its leading oncology compounds.

Thomas Wollman, Senior Vice President, Quintiles Global Central Laboratories said, Quintiles and Dako share the same goals for speed, quality and efficiency. By pairing our core competencies in translational medicine, biomarker discovery and managing clinical trials with Dako’s expertise in companion diagnostics, we can help physician investigators select the right patients for the right clinical trials, thereby accelerating the development of personalized oncology therapies for our customers in the New Health landscape.

As part of the alliance, Dako will develop cancer diagnostic tests, and Quintiles will conduct the tests as part of the clinical validation. Both Dako and Quintiles will continue to work independently with bio pharmaceutical companies and service providers in the industry.